RxDoctor Payments Data

Vanessa Sluder, NP

Family · Senatobia, MSNPI 1629301106

Payments from drug & device makers

$1,569in general payments, 2019–2025

Across 90 payments — averaging $17.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$347
  • AbbVie$283
  • Lilly USA, LLC$235
  • AstraZeneca$203
  • Boehringer Ingelheim$111
  • Abbott$100
  • plus $290 from 10 others

What the payments were for

  • Food & beverage$1,569100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,569 in reported general payments places this provider in the 75th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$76,827
Medicare patients
263
Services billed
3,086

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin24$33,281
OzempicSemaglutide20$26,355
Synjardy XrEmpagliflozin/Metformin Hcl21$24,219
LinzessLinaclotide15$23,550
TrulicityDulaglutide13$18,622
JanuviaSitagliptin Phosphate26$17,976
Xigduo XrDapaglifloz Propaned/Metformin15$16,839
MounjaroTirzepatide13$14,393
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$13,445
EliquisApixaban14$12,586
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$10,836
SymbicortBudesonide/Formoterol Fumarate23$8,942
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$3,283
Esomeprazole Magnesium18$3,139
Icosapent Ethyl12$2,630

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr$111$57,50045 claims
Lilly USA, LLCTrulicity, Mounjaro$235$33,01526 claims
Novo NordiskOzempic$347$26,35520 claims
AbbVieLinzess, Synthroid$283$25,47341 claims
AstraZenecaBreztri Aerosphere, Symbicort$203$19,77840 claims
GSKTrelegy Ellipta$43$13,44515 claims
PfizerEliquis$67$12,58614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,007 family providers in Mississippi.

Other family in Senatobia

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →